ArticleGut2002
Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium.
Article in Gut, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 130 citations in OpenAlex.
- Efficacy and Safety of Argon Plasma Coagulation for the Ablation of Barrett's Esophagus: A Systemic Review and Meta-Analysis.Gut and liver · 2024Pooled it
- Efficacy and durability of radiofrequency ablation for Barrett's Esophagus: systematic review and meta-analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2013Pooled it
- Treatment for Barrett's oesophagus.The Cochrane database of systematic reviews · 2010Pooled it
- A trial of radiofrequency ablation for anal intraepithelial neoplasia.International journal of colorectal disease · 2017Trial
- Prospective randomized trial of argon plasma coagulation ablation versus endoscopic surveillance of Barrett's esophagus in patients treated with antisecretory medication.Digestive diseases and sciences · 2009Trial
- Trial
- Long-term follow-up after complete ablation of Barrett's esophagus with argon plasma coagulation.World journal of gastroenterology · 2005Trial
- Trial
- Applications of cryotherapy in premalignant and malignant esophageal disease: Preventing, treating, palliating disease and enhancing immunogenicity?World journal of gastrointestinal oncology · 2025Review
- Endoscopic management of esophageal cancer.World journal of gastrointestinal oncology · 2019Review
- Management of Barrett Esophagus Following Radiofrequency Ablation.Gastroenterology & hepatology · 2019Article
- Durability of Endoscopic Treatment for Dysplastic Barrett's Esophagus.Current treatment options in gastroenterology · 2019Review
- Natural History of the Post-ablation Esophagus.Digestive diseases and sciences · 2018Review
- Endoscopic therapy for confirmed low-grade dysplasia in Barrett's esophagus.Translational gastroenterology and hepatology · 2018Review
- MicroRNA profile in neosquamous esophageal mucosa following ablation of Barrett's esophagus.World journal of gastroenterology · 2017Article
- Cleavage of E-Cadherin Contributes to Defective Barrier Function in Neosquamous Epithelium.Digestive diseases and sciences · 2016Article
- Argon plasma coagulation for superficial esophageal squamous-cell carcinoma in high-risk patients.World journal of gastroenterology · 2012Article
- Effective intra-esophageal acid control is associated with improved radiofrequency ablation outcomes in Barrett's esophagus.Digestive diseases and sciences · 2012Article
- Medical and endoscopic management of high-grade dysplasia in Barrett's esophagus.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2012Article
- Barrett's esophagus: endoscopic treatments II.Annals of the New York Academy of Sciences · 2011Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBarrett's epithelium (BE) has malignant potential. Neither acid suppression nor antireflux surgery produce consistent or complete regression of the metaplastic epithelium. Endoscopic thermoablation with argon plasma coagulation (APC) offers a different approach but factors influencing its outcome have not been systematically examined.
aimTo assess the efficacy of APC and factors influencing initial and one year outcome.
methodsFifty patients, mean age 61.4 years, mean BE length 5.9 cm (range 3-19), underwent APC therapy at four weekly intervals while receiving proton pump inhibitor (PPI) therapy. BE margins were marked by India ink tattooing and extent was documented by grid drawings, photography, and 2 cm interval quadrantic jumbo biopsies. Twenty four hour ambulatory oesophageal pH studies were done while on PPIs before and after APC therapy, and Bilitec bilirubin monitoring after APC completion.
resultsA total of 68% of patients achieved >90% BE ablation after a median of four APC sessions. Persistent BE (>10% original BE area) was associated with longer initial BE length despite more APC sessions. Persistent acid and bile reflux on PPIs, although commoner in this group, were not significantly different from those successfully ablated. Fifteen of 34 patients (44%) with successful macroscopic clearance had buried glands, present in 8.3% of a total of 338 biopsies. At the one year follow up, only 32% of those with initial successful ablation showed no recurrence. BE recurred or increased in most with mean segment length increases of 1.1 cm and 1.6 cm, respectively, in patients with previous full ablation and those with persistent BE. The presence of buried glands did not predict BE recurrence. Patients who reduced their PPI dose had significantly greater BE recurrence.
conclusionsAPC is most effective for shorter segment BE ablation but "buried" glands do occur. Recurrence of BE is common at one year, especially in those with initial persistent and/or long segment BE and those who reduce their PPI dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.